The Global Health Body Raises Alert Over Acute Shortage of Obesity Jabs
Less than a tenth of individuals that would benefit from obesity jabs including Wegovy are able to get them, warns the WHO as it publishes its first advice on the drugs.
Considering more than one billion people worldwide currently obese, it is calling for increased and just access to GLP-1 medication.
According to projections, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"The new guidelines acknowledges that excess weight is a chronic disease that can be addressed with comprehensive and continuous treatment," said WHO director-general Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are key hurdles to widespread access to the jabs that can aid individuals in losing considerable body mass, explains the body.
Weight-Loss Drug Supply Crisis
Even in the current most favorable case, the production of such drugs might only reach around 100 million people – under 10% of the global need, per the health organization.
The recommendation urges governments and firms to widen availability, through approaches such as voluntary licensing.
A patent on semaglutide – the primary component of a leading brand – is scheduled to end in a number of nations in 2026.
How Obesity Drugs Function
The injections imitate a body's own hormone to delay gastric emptying, reduce hunger and increase satiety so users reduce food intake.
Individuals commonly begin shedding pounds in the initial weeks of starting on the once-weekly jabs.
Research indicates users may put most of the weight back on after a year of stopping the treatment, because their usual appetite return.
To be above a healthy weight increases your chance for experiencing health problems, like type 2 diabetes, cardiovascular issues, brain attack, and certain malignancies.
Obesity concerns individuals in every country and was linked to millions of deaths worldwide in 2024, per the WHO.
